Matt Labella

About Matt Labella

My work sits at the intersection of molecular R&D and biopharma partnership — translating assay science into clinical and commercial reality. At Myriad Genetics I\'ve been part of the Precise MRD program since its earliest days as a bench scientist in 2021, and have grown with it through analytical validation, clinical development, and this month\'s alpha launch in breast cancer — the first commercial patients now being tested on a platform I helped build from the ground up. Today I lead the laboratory and scientific interface for a multi-year biopharma MRD partnership that has grown from pilot feasibility to 25 completed and ongoing clinical studies, five of which are active and revenue-generating — representing the first commercial revenue from the Precise MRD test. I also serve as R&D lead and inter-company liaison on a multinational oncology companion diagnostic program, coordinating molecular, automation, software, regulatory, and business development teams across two organizations at FDA IDE and EU IVDR validation levels. The science side matters to me too. My team\'s ctDNA work contributed to two peer-reviewed publications from the same ccRCC program — metastasis-directed radiotherapy outcomes in Lancet Oncology (2025) and the K-COMPASS prognostic model in European Urology (2026). The MONITOR-Breast prospective neoadjuvant study — where my team ran all ctDNA processing across 113 patients and 11+ serial timepoints — is submitted for ESMO 2026. I also co-developed a cfDNA fragmentomics RUO assay with GeneCentric Therapeutics, presented at AACR 2026. I\'m always interested in connecting with people working at the intersection of assay science and biopharma strategy — translational research, clinical development partnerships, companion diagnostics. Happy to connect.

Experience

1. Senior Manager, Scientist - Biopharma R & d

   Myriad Genetics

   Feb 2024 — Present · Salt Lake City, UT, US

   R&D lead and inter-company liaison for a multinational oncology companion diagnostic program (FDA IDE + EU IVDR), coordinating molecular, automation, software, regulatory, and BD teams across two organizations. Lab and scientific lead for a multi-year biopharma MRD partnership encompassing 25 completed and in-progress clinical studies — five active and revenue-generating, representing the first commercial revenue from the Precise MRD platform. Contributed to MRD data generation supporting two publications: metastasis-directed radiotherapy outcomes (Lancet Oncology 2025) and the K-COMPASS prognostic model (European Urology 2026). Lab team executed all ctDNA processing for the MONITOR-Breast prospective neoadjuvant study (113 patients, submitted ESMO 2026). Co-developed cfDNA fragmentomics RUO assay with GeneCentric Therapeutics (AACR 2026).

Education

• University of Utah

  Doctor of Philosophy - PhD, Biology

  2011 — 2019

• SUNY Geneseo

  BS, Biology

  2004 — 2008